Venus Remedies Limited, a Haryana-based leading research based company, has announced that the company has received patent for Tobracef from the Companies and Intellectual Property Registration Office (CIPRO), South Africa.

Tobracef is indicated for the treatment of complicated mixed bacterial infection of acute pulmonary exacerbations/custic fibrosis/chronic obstructive pulmonary disease. The product is a novel fixed dose combination of cephalosporin and aminoglycoside.

According to a Venus Remedies press release, Tobracef was launched in July 2008 in domestic market after going through stringent phase-III clinical as per GLP guidelines and DCGI approval. Within a year of launch in Indian market, the product has gained huge acceptance among medical fraternity. The product is under process of registration in many regulated and semi - regulated market.

The market for anti-infective related disorders is becoming increasingly challenging as growing number of infectious pathogens are becoming resistant to existing therapies. The resultant shift in R&D strategies has become a driving force behind market transformation. Venus Medicine Research Center (VMRC) has been focusing on developing drugs to counter resistance since past seven years. Tobracef is the result of dedicated and consistent team efforts of VMRC.